Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer

Phase 4

Completed

Conditions: Prostate Cancer

Interventions: Drug: Enzalutamide
Drug: Flutamide
Other: Androgen deprivation therapy

Registration Number: NCT02918968

Lead Sponsor: Astellas Pharma Inc

Brief Summary: The objective of this study was to compare the efficacy and safety of the combination therapy with enzalutamide + androgen deprivation therapy (ADT) and the combination therapy with flutamide + ADT in patients with castration resistant prostate cancer who had relapsed during combined androgen blockade (CAB) therapy with bicalutamide and ADT. This study also investigated the order of alternative antiandrogen therapy (AAT) by changing the 1st line medication after relapse of prostate-specific antigen (PSA).

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: Male

Target Recruitment: 206

Inclusion Criteria

Subject is diagnosed with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small-cell histology.
Subject on continuous ADT with Gonadotropin Releasing Hormone (GnRH) agonist/antagonist or bilateral orchiectomy.
Serum testosterone level below the target level at screening visit.
Subject with asymptomatic or mildly symptomatic prostate cancer.
Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Subject has progression of the disease as defined by rising PSA levels or progressive soft tissue or bony disease during CAB therapy in combination of bicalutamide and ADT.
A sexually active male subject and the subject's female partner who is of childbearing potential must use 2 acceptable birth control methods from screening to 3 months after the last dose of the study drug.
Subject must agree not to donate sperm from screening to 3 months after the last dose of the study drug.

Exclusion Criteria

Subject with severe concurrent diseases, infections, or complications.
Subject with confirmed or suspected brain metastasis or active leptomeningeal metastasis.
Subject with a history of malignant tumor other than prostate cancer in the past 5 years.
Subject hypersensitive to the ingredients of enzalutamide capsules or flutamide tablets.
Subject with a history of convulsive attack, or prone to convulsive attack.
Subject with liver disorder such as viral hepatitis and hepatic cirrhosis, or subject with Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) at screening visit higher than the upper limit of normal.
Subject received treatment for prostate cancer with cytocidal chemotherapy that includes anti androgenic agents other than bicalutamide, abiraterone, or estramustine.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Flutamide 375 mg 1st line AAT/Enzaltumide 160 mg 2nd line AAT	Androgen deprivation therapy	Participants received flutamide 125 mg tablets orally thrice daily after each meal as 1st line of AAT until confirmed PSA progression, other disease progression, or an intolerable adverse event. After confirmed PSA progression, other disease progression, or an intolerable adverse event. participants received enzalutamide 160 mg capsules orally once daily as 2nd line of AAT. Treatment with each drug was continued until the participant met any of the discontinuation criteria or until 2 years from the enrollment of the last participant (approximately 38 months).
Enzalutamide 160 mg 1st line AAT/Flutamide 375 mg 2nd line AAT	Androgen deprivation therapy	Participants received enzalutamide 160 mg capsules, orally once daily as 1st line of alternative antiandrogen therapy (AAT) until confirmed prostate-specific antigen (PSA) progression, other disease progression, or an intolerable adverse event. After confirmation of PSA progression, other disease progression, or an intolerable adverse event, participants received flutamide 125 mg tablets orally thrice daily after each meal as 2nd line of AAT. Treatment with each drug was continued until the participant met any of the discontinuation criteria or until 2 years from the enrollment of the last participant (approximately 38 months).
Enzalutamide 160 mg 1st line AAT/Flutamide 375 mg 2nd line AAT	Enzalutamide	Participants received enzalutamide 160 mg capsules, orally once daily as 1st line of alternative antiandrogen therapy (AAT) until confirmed prostate-specific antigen (PSA) progression, other disease progression, or an intolerable adverse event. After confirmation of PSA progression, other disease progression, or an intolerable adverse event, participants received flutamide 125 mg tablets orally thrice daily after each meal as 2nd line of AAT. Treatment with each drug was continued until the participant met any of the discontinuation criteria or until 2 years from the enrollment of the last participant (approximately 38 months).
Enzalutamide 160 mg 1st line AAT/Flutamide 375 mg 2nd line AAT	Flutamide	Participants received enzalutamide 160 mg capsules, orally once daily as 1st line of alternative antiandrogen therapy (AAT) until confirmed prostate-specific antigen (PSA) progression, other disease progression, or an intolerable adverse event. After confirmation of PSA progression, other disease progression, or an intolerable adverse event, participants received flutamide 125 mg tablets orally thrice daily after each meal as 2nd line of AAT. Treatment with each drug was continued until the participant met any of the discontinuation criteria or until 2 years from the enrollment of the last participant (approximately 38 months).
Flutamide 375 mg 1st line AAT/Enzaltumide 160 mg 2nd line AAT	Enzalutamide	Participants received flutamide 125 mg tablets orally thrice daily after each meal as 1st line of AAT until confirmed PSA progression, other disease progression, or an intolerable adverse event. After confirmed PSA progression, other disease progression, or an intolerable adverse event. participants received enzalutamide 160 mg capsules orally once daily as 2nd line of AAT. Treatment with each drug was continued until the participant met any of the discontinuation criteria or until 2 years from the enrollment of the last participant (approximately 38 months).
Flutamide 375 mg 1st line AAT/Enzaltumide 160 mg 2nd line AAT	Flutamide	Participants received flutamide 125 mg tablets orally thrice daily after each meal as 1st line of AAT until confirmed PSA progression, other disease progression, or an intolerable adverse event. After confirmed PSA progression, other disease progression, or an intolerable adverse event. participants received enzalutamide 160 mg capsules orally once daily as 2nd line of AAT. Treatment with each drug was continued until the participant met any of the discontinuation criteria or until 2 years from the enrollment of the last participant (approximately 38 months).

Primary Outcome Measures

Name	Time	Method
Time to PSA Progression With 1st Line AAT (TTPP1)	From date of randomization to the date of PSA progression in the 1st line AAT period (Up to 38 months)	TTPP1 was defined as the period from the date of randomization to the date of PSA progression in the 1st line AAT period. PSA progression was defined according to the consensus guidelines of prostate cancer clinical trials working group 2 (PCWG2). For participants with PSA declines at week 13, the PSA progression date was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir were documented, which was confirmed by a second consecutive value obtained 3 or more weeks later. For participants with no PSA decline at week 13, the PSA progression date was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the baseline were documented. Time to event analysis was performed using kaplan-meier (KM) estimates.

Secondary Outcome Measures

Name	Time	Method
Time to Treatment Failure of 2nd Line AAT (TTF2)	From date of randomization to discontinuation of 2nd line AAT (Up to 38 months)	TTF2 was defined as the period from randomization to study drug discontinuation of 2nd line AAT for any reason that includes disease progression, onset of AEs, participants request, or death. Time to event analysis was performed using kaplan-meier estimates.
Percentage of Participants Achieving at Least 50 or 90 Percent (%) Reduction From Baseline to Week 13 in Prostate Specific Antigen (PSA) Response at 1st Line AAT	Baseline and week 13	PSA response was defined as the lowest PSA at week 13 decreased by at least 50% or 90% from baseline in the 1st line AAT period. Data was reported per each disease stage (M0/N0, M0/N1, M1). 1) M0/N0: No distant metastasis and no lymph node metastasis. 2) M0/N1: Without distant metastasis, but with metastasis in lymph nodes distal to the aortic bifurcation. 3) M1: With distant metastasis (including metastasis in lymph nodes proximal to the aortic bifurcation).
Time to PSA Progression With 2nd Line AAT (TTPP2)	From date of randomization to the date of PSA progression in 2nd line AAT (Up to 38 months)	TTPP2 was defined as the period from day 1 of the 2nd line AAT to the date of PSA progression with the 2nd line AAT. PSA progression was defined according to the consensus guidelines of PCWG2. For participants with PSA declines at week 13, the PSA progression date was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir were documented, which was confirmed by a second consecutive value obtained 3 or more weeks later. For participants with no PSA decline at week 13, the PSA progression date was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the baseline were documented. Time to event analysis was performed using kaplan-meier estimates.
Percentage of Participants Achieving at Least 50 or 90 Percent (%) Reduction From Baseline and Up To Week 38 in Prostate Specific Antigen (PSA) Response at 1st Line AAT	Baseline and at least 3 weeks after, the lowest PSA decreased by at least 50% or 90% from baseline (Up to 38 months)	PSA response was defined as PSA decreased by at least 50% or 90% from baseline when at least 3 weeks passed after the lowest PSA decreased by at least 50% or 90% from baseline in the 1st line AAT period after baseline. Data was reported per each disease stage (M0/N0, M0/N1, M1). 1) M0/N0: No distant metastasis and no lymph node metastasis. 2) M0/N1: Without distant metastasis, but with metastasis in lymph nodes distal to the aortic bifurcation. 3) M1: With distant metastasis (including metastasis in lymph nodes proximal to the aortic bifurcation).
Time to PSA Decrease by 50% From Baseline With 1st Line AAT	From date of randomization to the day when the decrease of PSA from baseline by 50% is first identified (Up to 38 months)	Time to PSA decrease by 50% with 1st line AAT was defined as the period from the date of randomization to the day when the decrease of PSA from baseline by 50% is first identified. Time to event analysis was performed using kaplan-meier estimates. Data was reported per each disease stage (M0/N0, M0/N1, M1). 1) M0/N0: No distant metastasis and no lymph node metastasis. 2) M0/N1: Without distant metastasis, but with metastasis in lymph nodes distal to the aortic bifurcation. 3) M1: With distant metastasis (including metastasis in lymph nodes proximal to the aortic bifurcation).
Time to Treatment Failure of 1st Line AAT (TTF1)	From date of randomization to discontinuation of 1st line AAT (Up to 38 months)	TTF1 was defined as the period from randomization to study drug discontinuation of 1st line AAT for any reason that includes disease progression, onset of adverse events (AEs), participants request, or death. Time to event analysis was performed using kaplan-meier estimates. Data was reported per each disease stage (M0/N0, M0/N1, M1). 1) M0/N0: No distant metastasis and no lymph node metastasis. 2) M0/N1: Without distant metastasis, but with metastasis in lymph nodes distal to the aortic bifurcation. 3) M1: With distant metastasis (including metastasis in lymph nodes proximal to the aortic bifurcation).
Radiographic Progression-free Survival (rPFS)	From date of randomization to the time when radiographic disease progression is observed or death of any cause (up to 38 months)	rPFS was defined as the period from randomization to the time when radiographic disease progression is observed or death of any cause during the study period, whichever occurs earlier. Time to event analysis was performed using kaplan-meier estimates. Data was reported per each disease stage (M0/N0, M0/N1, M1). 1) M0/N0: No distant metastasis and no lymph node metastasis. 2) M0/N1: Without distant metastasis, but with metastasis in lymph nodes distal to the aortic bifurcation. 3) M1: With distant metastasis (including metastasis in lymph nodes proximal to the aortic bifurcation).

Trial Locations

Locations (47): Site JP00051
🇯🇵
Iizuka, Fukuoka, Japan
Site JP00019
🇯🇵
Sagamihara, Kanagawa, Japan
Site JP00024
🇯🇵
Nagoya, Aichi, Japan
Site JP00038
🇯🇵
Matsuyama, Ehime, Japan
Site JP00045
🇯🇵
Isesaki, Gunma, Japan
Site JP00005
🇯🇵
Maebashi, Gunma, Japan
Site JP00001
🇯🇵
Sapporo, Hokkaido, Japan
Site JP00002
🇯🇵
Sapporo, Hokkaido, Japan
Site JP00049
🇯🇵
Utsunomiya, Tochigi, Japan
Site JP00011
🇯🇵
Bunkyo-ku, Tokyo, Japan
Site JP00020
🇯🇵
Yokohama, Kanagawa, Japan
Site JP00021
🇯🇵
Yokohama, Kanagawa, Japan
Site JP00033
🇯🇵
Kurashiki, Okayama, Japan
Site JP00022
🇯🇵
Hamamatsu, Shizuoka, Japan
Site JP00014
🇯🇵
Nakano-ku, Tokyo, Japan
Site JP00016
🇯🇵
Shinagawa-ku, Tokyo, Japan
Site JP00044
🇯🇵
Yokosuka, Kanagawa, Japan
Site JP00013
🇯🇵
Koto-ku, Tokyo, Japan
Site JP00017
🇯🇵
Bunkyo-ku, Tokyo, Japan
Site JP00018
🇯🇵
Shinjuku-ku, Tokyo, Japan
Site JP00053
🇯🇵
Chiba, Japan
Site JP00032
🇯🇵
Osaka, Japan
Site JP00037
🇯🇵
Tokushima, Japan
Site JP00025
🇯🇵
Nagoya, Aichi, Japan
Site JP00054
🇯🇵
Hakodate, Hokkaido, Japan
Site JP00043
🇯🇵
Ota, Gunma, Japan
Site JP00048
🇯🇵
Sapporo, Hokkaido, Japan
Site JP00055
🇯🇵
Mito, Ibaraki, Japan
Site JP00046
🇯🇵
Kashihara, Nara, Japan
Site JP00028
🇯🇵
Hirakata, Osaka, Japan
Site JP00030
🇯🇵
Osakasayama, Osaka, Japan
Site JP00027
🇯🇵
Suita, Osaka, Japan
Site JP00009
🇯🇵
Kitaadachi-gun, Saitama, Japan
Site JP00034
🇯🇵
Ube, Yamaguchi, Japan
Site JP00010
🇯🇵
Chiba, Japan
Site JP00039
🇯🇵
Fukuoka, Japan
Site JP00035
🇯🇵
Hiroshima, Japan
Site JP00040
🇯🇵
Fukuoka, Japan
Site JP00050
🇯🇵
Fukuoka, Japan
Site JP00026
🇯🇵
Kyoto, Japan
Site JP00006
🇯🇵
Nagano, Japan
Site JP00008
🇯🇵
Nagano, Japan
Site JP00041
🇯🇵
Nagasaki, Japan
Site JP00029
🇯🇵
Osaka, Japan
Site JP00031
🇯🇵
Osaka, Japan
Site JP00042
🇯🇵
Saga, Japan
Site JP00052
🇯🇵
Toyama, Japan